{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:29:20Z","timestamp":1770074960931,"version":"3.49.0"},"reference-count":64,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T00:00:00Z","timestamp":1577232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER-Compete2020","award":["POCI-01-0145-FEDER-007274"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274"]}]},{"name":"PORTUGAL 2020","award":["NORTE-01-0145-FEDER-000029"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000029"]}]},{"name":"PORTUGAL 2020","award":["NORTE-01-0145-FEDER-000003"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000003"]}]},{"name":"PORTUGAL 2020","award":["POCI-01-0145-FEDER-022184"],"award-info":[{"award-number":["POCI-01-0145-FEDER-022184"]}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["PTDC\/BBB-ECT\/2518\/2014"],"award-info":[{"award-number":["PTDC\/BBB-ECT\/2518\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"FCT","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-30164"],"award-info":[{"award-number":["POCI-01-0145-FEDER-30164"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FEDER-POCI-FCT","award":["POCI-01-0145-FEDER-016390"],"award-info":[{"award-number":["POCI-01-0145-FEDER-016390"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Gastric Cancer (GC) is one of the most common and deadliest types of cancer in the world. To improve GC prognosis, increasing efforts are being made to develop new targeted therapies. Although FGFR2 genetic amplification and protein overexpression in GC have been targeted in clinical trials, so far no improvement in patient overall survival has been found. To address this issue, we studied genetic and epigenetic events affecting FGFR2 and its splicing regulator ESRP1 in GC that could be used as new therapeutic targets or predictive biomarkers. We performed copy number variation (CNV), DNA methylation, and RNA expression analyses of FGFR2\/ESRP1 across several cohorts. We discovered that both genes were frequently amplified and demethylated in GC, resulting in increased ESRP1 expression and of a specific FGFR2 isoform: FGFR2-IIIb. We also showed that ESRP1 amplification in GC correlated with a significant decreased expression of FGFR2-IIIc, an alternative FGFR2 splicing isoform. Furthermore, when we performed a survival analysis, we observed that patients harboring diffuse-type tumors with low FGFR2-IIIc expression revealed a better overall survival than patients with FGFR2-IIIc high-expressing diffuse tumors. Our results encourage further studies on the role of ESRP1 in GC and support FGFR2-IIIc as a relevant biomarker in GC.<\/jats:p>","DOI":"10.3390\/cancers12010070","type":"journal-article","created":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T11:07:48Z","timestamp":1577272068000},"page":"70","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7409-9651","authenticated-orcid":false,"given":"Sara Pinto","family":"Teles","sequence":"first","affiliation":[{"name":"Ipatimup\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Master in Oncology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP), 4050-313 Porto, Portugal"}]},{"given":"Patr\u00edcia","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Ipatimup\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-8613","authenticated-orcid":false,"given":"Marta","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Ipatimup\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"given":"Joana","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Ipatimup\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}]},{"given":"Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Ipatimup\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Department of Computer Science, Faculty of Sciences, University of Porto, Rua Campo Alegre 1021\/1055, 4169-007 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-2264","authenticated-orcid":false,"given":"Carla","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Ipatimup\u2014Institute of Molecular Pathology and Immunology, University of Porto, Rua J\u00falio Amaral de Carvalho 45, 4200-135 Porto, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"},{"name":"Department Pathology and Oncology Faculty of Medicine University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11894-017-0575-8","article-title":"Changing Trends in Stomach Cancer Throughout the World","volume":"19","author":"Balakrishnan","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000473881","article-title":"Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications","volume":"85","author":"Gullo","year":"2018","journal-title":"Pathobiology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S1470-2045(17)30566-1","article-title":"Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Catenacci","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1634\/theoncologist.2016-0038","article-title":"A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction","volume":"21","author":"Shah","year":"2016","journal-title":"Oncologist"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification","volume":"28","author":"Bang","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","article-title":"Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma","volume":"18","author":"Nagatsuma","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3892\/mco.2014.293","article-title":"Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer","volume":"2","author":"Murase","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study","volume":"110","author":"Su","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19748","DOI":"10.18632\/oncotarget.7782","article-title":"Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma","volume":"7","author":"Tokunaga","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_21","first-page":"518","article-title":"Preferential expression of the third immunoglobulin-like domain of K-sam product provides keratinocyte growth factor-dependent growth in carcinoma cell lines","volume":"54","author":"Ishii","year":"1994","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","article-title":"Receptor specificity of the fibroblast growth factor family","volume":"271","author":"Ornitz","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_23","first-page":"4627","article-title":"The human fibroblast growth factor receptor genes: A common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain","volume":"11","author":"Johnson","year":"1991","journal-title":"Mol. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/j.1460-2075.1992.tb05240.x","article-title":"A confined variable region confers ligand specificity on fibroblast growth factor receptors: Implications for the origin of the immunoglobulin fold","volume":"11","author":"Yayon","year":"1992","journal-title":"EMBO J."},{"key":"ref_25","first-page":"721","article-title":"Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells","volume":"31","author":"Yoshino","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0002-9440(10)65562-9","article-title":"Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer","volume":"153","author":"Ishiwata","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_27","first-page":"987","article-title":"Expression of keratinocyte growth factor receptor (KGFR\/FGFR2 IIIb) in human uterine cervical cancer","volume":"11","author":"Kurban","year":"2004","journal-title":"Oncol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/path.1617","article-title":"Expression of keratinocyte growth factor\/fibroblast growth factor-7 and its receptor in human lung cancer: Correlation with tumour proliferative activity and patient prognosis","volume":"204","author":"Yamayoshi","year":"2004","journal-title":"J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2353\/ajpath.2007.060935","article-title":"Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer","volume":"170","author":"Cho","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.onc.1200830","article-title":"Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas","volume":"14","author":"Chopin","year":"1997","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3892\/or.2014.3200","article-title":"Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells","volume":"32","author":"Shoji","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pros.10104","article-title":"Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate","volume":"52","author":"Naimi","year":"2002","journal-title":"Prostate"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11336","DOI":"10.1073\/pnas.191377098","article-title":"Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis","volume":"98","author":"Zhang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","first-page":"1509","article-title":"Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2","volume":"58","author":"Matsubara","year":"1998","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.1038\/sj.onc.1203186","article-title":"Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer","volume":"18","author":"Ricol","year":"1999","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrm1835","article-title":"Complex networks orchestrate epithelial-mesenchymal transitions","volume":"7","author":"Thiery","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.semcancer.2012.04.003","article-title":"Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT)","volume":"22","author":"Warzecha","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/sj.onc.1201498","article-title":"Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer","volume":"15","author":"Carstens","year":"1997","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/1078-0432.CCR-12-3708","article-title":"Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas","volume":"19","author":"Zhao","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: Protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000441149","article-title":"Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer","volume":"82","author":"Han","year":"2015","journal-title":"Pathobiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2217\/fon-2019-0141","article-title":"Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design","volume":"15","author":"Catenacci","year":"2019","journal-title":"Future Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.bbrc.2007.04.051","article-title":"Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines","volume":"357","author":"Park","year":"2007","journal-title":"Biochem. Biophys Res. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/rna.6.5.9606","article-title":"The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events","volume":"6","author":"Warzecha","year":"2009","journal-title":"RNA Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/emboj.2010.195","article-title":"An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition","volume":"29","author":"Warzecha","year":"2010","journal-title":"EMBO J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s10120-015-0467-2","article-title":"Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer","volume":"19","author":"Wang","year":"2016","journal-title":"Gastric. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/5584_2016_50","article-title":"Dual Roles for Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) in Cancer Progression","volume":"925","author":"Hayakawa","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1038\/onc.2013.392","article-title":"Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases","volume":"33","author":"Ueda","year":"2014","journal-title":"Oncogene"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/ncomms1892","article-title":"Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell","volume":"3","author":"Yae","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1101\/gad.2037511","article-title":"CpG islands and the regulation of transcription","volume":"25","author":"Deaton","year":"2011","journal-title":"Genes Dev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.molcel.2009.01.025","article-title":"ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing","volume":"33","author":"Warzecha","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_53","first-page":"875","article-title":"Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma","volume":"21","author":"Toyokawa","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_54","first-page":"307","article-title":"Expression of keratinocyte growth factor receptor correlates with expansive growth and early stage of gastric cancer","volume":"28","author":"Matsunobu","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","article-title":"Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil","volume":"145","author":"Lei","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Fagoonee, S., Bearzi, C., Di Cunto, F., Clohessy, J.G., Rizzi, R., Reschke, M., Tolosano, E., Provero, P., Pandolfi, P.P., and Silengo, L. (2013). The RNA binding protein ESRP1 fine-tunes the expression of pluripotency-related factors in mouse embryonic stem cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072300"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bbrc.2011.02.082","article-title":"Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer","volume":"406","author":"Kwon","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_58","unstructured":"(2019, November 14). GDC Data Portal, Available online: https:\/\/portal.gdc.cancer.gov\/."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1541-7786.MCR-13-0614","article-title":"Mutational landscape of the essential autophagy gene BECN1 in human cancers","volume":"12","author":"Laddha","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2011.06.034","article-title":"Systematic assessment of reduced representation bisulfite sequencing to human blood samples: A promising method for large-sample-scale epigenomic studies","volume":"157","author":"Wang","year":"2012","journal-title":"J. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"D853","DOI":"10.1093\/nar\/gky1095","article-title":"The UCSC Genome Browser database: 2019 update","volume":"47","author":"Haeussler","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_63","unstructured":"(2014). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: http:\/\/www.R-project.org\/."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis, Springer.","DOI":"10.1007\/978-3-319-24277-4_9"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/1\/70\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:45:45Z","timestamp":1760190345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/1\/70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,25]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["cancers12010070"],"URL":"https:\/\/doi.org\/10.3390\/cancers12010070","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,25]]}}}